E vidence is emerging that derangements in cardiac energy metabolism and mitochondrial function contribute to the pathological remodeling that leads to heart failure (HF). During pathological hypertrophic growth caused by chronic pressure overload, the heart undergoes a reprogramming of its fuel preference to a fetal format, shifting toward glucose, away from reliance on fatty acids, the chief energy substrate for the normal adult mammalian heart. [1] [2] [3] [4] [5] [6] [7] [8] The capacity of cardiac mitochondria to generate ATP is also compromised during the development of HF. Studies conducted in animal models and in humans have shown that myocardial high-energy phosphate stores (phosphocreatine levels), the main reservoir source of ATP, are reduced in the hypertrophied and failing heart. [9] [10] [11] [12] [13] The potential role of fuel metabolic and bioenergetic disturbances as causal in HF is also supported by the observation that human inborn errors in mitochondrial fuel catabolism and ATP production cause cardiomyopathy. [14] [15] [16] 
the fuel and energy metabolic disturbances and corresponding upstream regulatory events occurring during the early stages of HF is an important first step toward the identification of new therapeutic targets for the early-stage treatment of HF.
In this study, unbiased transcriptomic and targeted quantitative metabolomic profiling were conducted to identify metabolic gene regulatory events and corresponding changes in metabolite pools that occur during the development of HF because of pressure overload in mice. The results were compared with that of an adaptive form of cardiac hypertrophy secondary to endurance exercise training. Surprisingly, we found that although transcriptional control of fatty acid oxidation (FAO) was altered, many genes involved in downstream mitochondrial energy transduction and ATP synthesis were not significantly regulated in the early stages of HF or in the exercise-trained heart. In striking contrast, myocardial metabolite profiles were distinct across each cardiac phenotype, providing robust signatures for the transition to HF, as well as distinguishing pathological versus physiological forms of cardiac hypertrophy.
Methods
An expanded Methods section, including all procedures used in this report, is available in the Data Supplement. In brief, all animal experiments and euthanasia protocols were conducted in strict accordance with the National Institute of Health guidelines for humane treatment of animals and approved by the Institutional Animal Care and Use Committee at the Sanford-Burnham Medical Research Institute at Lake Nona. Eight-week-old female C57BL/6J mice in the following groups were used: compensated hypertrophy (CH) versus sham controls; HF versus sham controls; physiological hypertrophy (PH) versus sedentary controls. CH was achieved by transverse aortic constriction (TAC). HF was achieved by TAC plus a small apical myocardial infarction. Mice were harvested 1 month after each procedure. PH was achieved by 8 weeks on a voluntary running wheel. At the end of all studies, hearts were excised and transcriptomic and metabolomic profiling was performed. The gene array data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE56348.
Validation by quantitative reverse transcription-polymerase chain reaction was performed. Primer sets can be found in Table I in the Data Supplement. Data were analyzed using nonparametric Mann-Whitney test (GraphPad Prism 6), 2-tailed, unless otherwise noted. For pathway analysis, Fisher exact test was used to denote significance. For all statistics, the level of significance was set at P<0.05, and data are reported as mean±SD unless otherwise noted.
Results
To identify metabolic changes that occur in the relatively early stages of pressure overload-induced cardiac left ventricular (LV) remodeling, a mouse model of chronic pressure overload was used. LV pressure overload was induced by performing TAC on female C57BL/6J mice as previously described. 17 In this model, mice develop significant LV hypertrophy with preserved systolic LV function at the 4-week time point after the TAC procedure, referred to here as CH. As expected, the CH group developed significant LV hypertrophy 4 weeks after TAC compared with sham-operated controls [(bi-ventricle weight/ body weight, 6.55±1.58 (n=13) versus 4.00±0.22 (n=17); P<0.001)] with preserved LV function (data not shown). In a second experimental group, TAC was combined with a small apical myocardial infarction achieved by placing a ligature in the distal portion of the left anterior descending coronary artery, resulting in global LV systolic and diastolic dilatation and significantly reduced LV ejection fraction 4 weeks after the procedure (Figure I and Table II in the Data Supplement) , termed the HF group. Notably, this HF model results in global pathological remodeling [(bi-ventricle weight/body weight, 7.08±1.21(n=23) versus 4.10±0.32 (n=30); P<0.001)], without evidence of fibrosis outside of the excised infarct region, consistent with early stage HF (data not shown). The apical myocardial infarction alone did not result in significant LV remodeling ( Figure I in the Data Supplement). Transcriptomic and quantitative targeted metabolomic profiling were conducted on ventricular samples harvested from CH and HF groups and corresponding sham-operated controls. The infarcted apical region was removed from the HF hearts and corresponding tissue region was removed from sham-operated control samples.
Transcriptomic Profiling of Pathological Cardiac Hypertrophy and Heart Failure
Gene expression profiling was conducted on samples from the 4 groups followed by informatics analyses (see Methods in the Data Supplement). Genes with a posterior probability of ≥0.95 were considered significantly differentially expressed (DE) relative to corresponding sham-operated control mice. One thousand and eighty genes were DE in the CH group (731 upregulated; 349 downregulated) and 1627 genes were regulated in the HF group (947 upregulated; 680 downregulated). Notably, the majority of genes that were DE in the CH group were also DE in the HF group ( Figure 1A) . In addition, genes that were DE in both CH and HF were almost always directionally concordant ( Figure 1B ). The directional expression of DE genes in CH and HF groups was highly positively correlated (R 2 =0.9 and P=2×10 -16 ; Figure 1B ). These results indicate that the majority of gene regulatory events in HF were initiated in CH.
Ingenuity Pathway Analysis was conducted with the gene expression data sets to identify regulated pathways and biological processes in the CH and HF groups. Separate analyses were performed for genes upregulated or downregulated in each group compared with corresponding controls. Multiple pathways involved in metabolism were represented by downregulated genes in both CH and HF groups (Tables III and IV in the Data Supplement). In contrast, and consistent with the hypertrophic growth response, many pathways involved in inflammation, growth, and cellular assembly/organization/ movement were identified by upregulated genes in both CH and HF groups (Tables III and IV in the Data Supplement) . A significant proportion of downregulated genes were noted in pathways involved in fatty acid uptake, transport, and catabolism in the CH and HF groups, with a greater number in the latter group (Tables III and IV in the Data Supplement) . Specifically, genes involved in FAO (Acaa2, Ecil, Acadvl, and Hadh), fatty acid uptake (Slc27a1, Acsl5, and Acsl6), and acyl trafficking (Cpt2) were significantly downregulated in the HF group (Table V in the Data Supplement). The extent of this regulation among several key lipid utilization pathways is shown in greater detail in Figure 2 . These results serve as a form of validation for the transcriptional profiling data set, given that many published studies have shown that genes involved in cardiac myocyte fatty acid uptake and oxidation are downregulated in the hypertrophied and failing heart. 8, [18] [19] [20] [21] [22] The transcriptomic analyses identified amino acid metabolism as a second regulated metabolic pathway category in the CH and HF samples. Regulation in this category largely reflected downregulation of genes involved in amino acid degradation pathways (Tables III and IV in the Data Supplement) . Specifically, expression of genes involved in the degradation of proline, alanine, tryptophan, and branched-chain amino acids were downregulated (Table VI in the Data Supplement; Figure 3 ). These results are of interest, given that several of these pathways can serve as sources of anaplerotic input into the tricarboxylic acid (TCA) cycle.
Several published gene expression profiling studies conducted largely in severe end-stage HF in several different models and species have demonstrated downregulated expression of genes involved in the electron transport complex (ETC) and oxidative phosphorylation (OXPHOS). [23] [24] [25] [26] Surprisingly, we found little regulation of genes involved in ETC, OXPHOS, or the TCA cycle in either the CH (data not shown) or HF groups ( Figure II in the Data Supplement).
Metabolomic Profiling of Pathological Cardiac Hypertrophy and Heart Failure
The transcriptomic data did not identify many signatures that distinguished HF from CH, particularly in metabolic pathways. Accordingly, metabolomic profiling was conducted to determine whether metabolite levels could provide additional insight into the energy metabolic changes that occur during the progression from compensated cardiac hypertrophy to HF. Samples from the CH and HF groups and corresponding controls were subjected to targeted quantitative metabolomics using mass spectrometry to define levels of metabolites in 3 main classes relevant to several mitochondrial fuel metabolic pathways: acylcarnitines (FAO), organic acids (lactate/pyruvate oxidation and the TCA cycle), and amino acids. In contrast to the profile of metabolic gene regulation, the metabolomics data revealed a distinctly different pattern in the HF group compared with the CH group (Table VII in the Data Supplement) . Indeed, there were relatively few differences in metabolite levels from the CH samples compared with the control samples. The most striking distinguishing metabolite signature in the HF group was exhibited in the acylcarnitine profile. Levels of many acylcarnitine species were increased in the HF group compared with controls ( Figure 4 ; Table VII in the Data Supplement). This was particularly notable for the long-chain (C14-C18) species. In addition, C2 carnitine levels (acetylcarnitine) were significantly increased in the HF samples. Consistent with increased levels of acylcarnitine esters, free carnitine levels (C0 carnitine) were modestly but significantly decreased in the HF group (Figure 4) .
The organic acid profile also revealed interesting differences between the CH and the HF groups. First, lactate levels and the lactate/pyruvate ratio were increased in HF but not CH, suggesting reduced flux of pyruvate into the TCA cycle with diversion to lactate ( Figure 5A ; Table VII in the Data  Supplement) . Second, levels of most TCA cycle intermediates (fumarate, malate, and α-ketoglutarate) were decreased in HF ( Figure 5B ). One exception was succinate, which was increased in the HF group ( Figure 5B ). The amino acid profile was less remarkable ( Figure 5C ; Table VII in the Data  Supplement) . However, a few modest but significant differences were noted, including increased levels of Asx (aspartic acid/asparagine) in the HF group ( Figure 5C ). In addition, with minor exceptions, changes in cardiac metabolites were not reflected in circulating plasma metabolite levels (Table  VIII in the Data Supplement) . Notably, a small but significant increase in some branched-chain amino acids (Leu/Ile) was observed in the plasma but not myocardium of the HF group. The observed elevation of long-chain acylcarnitine species together with a general reduction in TCA cycle intermediates in the HF group suggested a bottleneck of carbon flux within the FAO pathway. The reduced expression of a subset of genes involved in FAO observed in the transcriptomic profile in HF samples ( Table V in the Data Supplement) is consistent with this hypothesis. To explore this further, quantitative PCR was used to determine the level of representative genes involved in the cellular uptake and mitochondrial β-oxidation of long-chain fatty acids, some of which were identified as downregulated in the gene expression array data. The expression of genes encoding the fatty acid transporter (Slc27a1) and enzymes involved in mitochondrial fatty acid uptake and oxidation (Cpt2 and Acadvl) were all significantly downregulated only in the HF group ( Figure 6A ). In addition, expression of the gene encoding Ehhadh, a peroxisomal β-oxidation enzyme, was also downregulated in the HF samples ( Figure 6A ). Consistent with reduced expression of genes involved in long-chain FAO, palmitoylcarnitine-driven state 3 respiration was significantly diminished in isolated cardiac muscle strips in the HF samples compared with control ( Figure 6B ). In contrast, respiration rates with pyruvate as a substrate were unchanged in the HF group, consistent with the conclusion that the deficit in palmitoylcarnitine-driven respiration in HF is a result of a decreased capacity for FAO ( Figure 6B ).
To determine whether post-transcriptional changes in FAO enzyme levels contribute to the alteration in acylcarnitine levels, immunoblotting experiments were conducted on a subset of FAO enzymes for which the corresponding transcript was downregulated (very long-chain acyl-CoA dehydrogenase) or unchanged (medium-chain acyl-CoA dehydrogenase and long-chain acyl-CoA dehydrogenase). Consistent with the transcriptional profiling results, levels of very long-chain acyl-CoA dehydrogenase protein were reduced in the HF samples, whereas long-chain acyl-CoA dehydrogenase and medium-chain acyl-CoA dehydrogenase levels were unchanged ( Figure IIIA in the Data Supplement).
Transcriptomic/Metabolomic Profiling of Physiological Cardiac Hypertrophy
We next conducted cardiac transcriptomic and metabolomic profiling in an adaptive (physiological) cardiac growth state for comparison with the pressure overload data sets. To this end, cardiac ventricular samples obtained from C57BL/6J female mice subjected to a nocturnal wheel running-based exercise training regimen for 8 weeks were compared with sex-, strain-, and age-matched control samples. This intervention has been shown to result in PH of the LV, 27 albeit to a lesser degree than that achieved with the pressure overload regimen. The training regimen resulted in an ≈10% increase in bi-ventricle weight/ body weight (Table IX in The gene expression profiling results for the PH samples (compared with sedentary controls) revealed minimal regulation, with only 6 DE genes, none of which were within metabolic pathways (Table X in the Data Supplement). In contrast, significant changes were observed in the metabolome of the PH samples. Interestingly, the pattern of metabolite changes observed in the PH group was strikingly distinct from that of the HF profile. In contrast to the increase in long-chain acylcarnitines observed in HF, the levels of many medium-and long-chain acylcarnitines were decreased in the PH samples ( Figure 7A ; Table VII in the Data Supplement). In addition, there was no change in acetylcarnitine levels in the PH group in contrast to the observed elevation in HF ( Figures 7A and  4 ; Table VII in the Data Supplement). Differences were also noted in the organic acid species. Although both HF and PH exhibited reduced levels of a shared subset of organic acids (fumarate and malate), levels of succinate and lactate were reduced in PH but elevated in HF (Figures 7B, 5A , and 5B; 
Comparative Analysis of Transcriptomic and Metabolomic Profiles Across the Phenotypic Groups
We next compared the collective results of our transcriptomic and metabolomic analyses. This comparative analysis is depicted in heat maps (Figure 8 ) displaying the level and direction of differential expression compared with the corresponding controls. This comparative analysis, which was restricted to the subset of genes involved in mitochondrial fuel and energy metabolism relevant to the metabolites measured in the metabolomic analyses, led to several major conclusions. First, as noted earlier, a subset of genes involved in cellular fatty acid uptake/oxidation were downregulated in both the CH and, to a greater extent, the HF groups. Second, in contrast to the lipid utilization genes, the majority of genes involved in downstream mitochondrial energy transduction pathways, including ETC and OXPHOS, were not significantly regulated in the hypertrophied and failing heart. This observation is further highlighted by comparing the metabolic gene expression profiles in the CH and HF samples with the corresponding gene expression data obtained previously 28 from the hearts of mice deficient for the transcriptional coactivators, PGC-1α and PGC-1β, master regulators of genes involved in mitochondrial energy metabolism [29] [30] [31] [32] ( Figure 8A ). Third, few gene regulatory changes were observed in the hearts undergoing adaptive physiological cardiac hypertrophy (PH group; Figure 8A) . In contrast to the transcriptomic results, the metabolomic signatures served as a robust correlate of the cardiac phenotype ( Figure 8B ), distinguishing the CH, HF, and PH groups ( Figure 8B ). This was particularly evident on analysis of acylcarnitine species, many of which were unchanged in CH, increased in HF, and decreased in PH. The organic acid profile was also distinct among the metabolites as described earlier. Taken together, these results indicate that metabolite levels distinguished the cardiac hypertrophic phenotype and that post-transcriptional regulatory events contribute to the metabolic reprogramming that occurs in HF and PH. In addition, many observed changes in gene expression do not correlate with changes in metabolite pool size or cardiac dysfunction. This latter point is underscored by the observed lack of alterations in metabolite pools in the hearts of the PGC-1αβ -/hearts, which exhibit widespread downregulation in the expression of genes involved in mitochondrial metabolism ( Figure 8A ), yet exhibit normal cardiac function 28 and minimal changes in the metabolome ( Figure 8B ).
Discussion
Herein we undertook an unbiased approach to identify changes in energy metabolic gene expression and metabolite pools in several forms of cardiac hypertrophy and in the early stages of HF in a mouse model. The results demonstrated the power of using combined unbiased molecular profiling to define signatures of complex physiological and disease states. The transcriptional profiling results were remarkable for the lack of changes in expression of genes involved in ETC and OXPHOS. These results were surprising given that several previously published studies conducted in HF animal models and in humans with HF have shown reduced expression of ETC and OXPHOS genes and proteins. [23] [24] [25] [26] However, most of these studies focused on later stages of HF, suggesting that many of the observed metabolic gene regulatory events reflect irreversible mitochondrial dysfunction and myocyte death. In this study, focused on earlier stages with less severe pathological cardiac remodeling, we found a more selective pattern of altered metabolic gene regulation, including a significant subset of genes involved in lipid and amino acid metabolism. The observed reduction in expression of genes involved in mitochondrial FAO serve as a validation of our gene expression profiling, given that this pathway has been shown to be downregulated in many studies of pressure overload-induced cardiac hypertrophy and HF, in a variety of animal models and humans. 8, [18] [19] [20] [21] [22] We also found that expression of a subset of genes involved in amino acid degradation pathways were downregulated in CH and HF. The relevance of this finding is unclear but could relate to the balance between growth and catabolism. Specifically, cardiac hypertrophic growth requires activation of anabolic pathways involved in protein synthesis, which may result in feedback suppression of amino acid degradation pathways. This finding could also have implications for fuel metabolism, given that several of the downregulated amino acid catabolic pathways serve as an important source of anaplerotic carbon for the TCA cycle.
The metabolite profile served to robustly distinguish between the various cardiac phenotypes in this study. Many species in the acylcarnitine profile were elevated in the HF group, but were normal in CH. In addition, elevations in lactate and acetylcarnitine levels, along with a reduction in most organic acid TCA cycle intermediates, were specific to the HF samples. Taken together, this metabolite accumulation pattern suggests a bottleneck in carbon flux (fatty acids and glucose) into the TCA cycle, which could reduce capacity to generate the reducing equivalents needed to generate ATP contributing to contractile dysfunction. During preparation of this article, Sansbury et al 33 reported the results of global metabolomic profiling in a mouse model of TAC and myocardial infarction. In contrast to our results, this study reported a reduced level of acylcarnitines in the TAC and myocardial infarction models. The basis for this difference is unknown but could relate to coexisting severe ischemic insult or the duration of the HF (8 weeks in the study by Sansbury et al). Taken together, these findings suggest the interesting possibility that the myocardial metabolite profile reflects stage and etiology of the HF.
The metabolite profile was also regulated to a greater extent than the transcriptome in the exercise-trained heart. Interestingly, the regulated metabolite levels in the adaptive hypertrophy (PH) samples were generally directionally discordant from the pattern observed in the HF group. Specifically, in contrast to the failing heart, many acylcarnitine and organic acid species were concordantly decreased in the trained heart, suggesting matched carbon flux (absence of bottlenecking). Consistent with this conclusion, acetylcarnitine and lactate levels were normal. It should be noted that several previously published studies have shown a somewhat larger number of genes regulated in heart after exercise training. [34] [35] [36] [37] [38] The basis for this difference is not clear but could relate to training protocol, species, or degree of cardiac hypertrophy achieved.
Several limitations of this study should be noted. First, the studies were conducted only with female animals. Accordingly, we cannot conclude that the same results will be seen in male mice. Second, the HF model involved pressure overload together with a small apical infarct, which results in a predictable global LV dilatation and reduced ejection fraction. This approach allowed us to compare animals with compensated (CH) versus decompensated (HF) LV hypertrophy at the same relatively early time point (4 weeks). It is possible that the molecular profiling results shown here will differ from other HF models. Future comparative studies will be important to address this question.
The striking differences observed between the transcriptomic and metabolite profiles suggest that significant post-translational regulatory events may be operative in the metabolic reprogramming that occurs during the early stages of HF. Evidence is emerging that changes in the levels of mitochondrial metabolite pools, such as acetyl-CoA and succinyl-CoA, can lead to modification of mitochondrial enzyme function through acetylation and succinylation, respectively. [39] [40] [41] [42] [43] [44] [45] Indeed, a recent study has shown that HF in mice caused by targeted disruption of Ndufs4 involves a significant component of mitochondrial protein hyperacetylation and alterations in metabolite pools. 42 It will be of significant interest to determine whether such post-translational changes are relevant to the metabolic derangements that occur during the early stages of HF.
